Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05806060 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05806060 · ClinicalTrials.gov record · last posted 2026-03-25

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Study acronym: BCTOP-T-M01
StatusRecruiting
PhasePhase 3
Started2023-04-25
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 25, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The study is being conducted to evaluate VEGFR BP102 with nab-paclitaxe or treatment of physician's choice (TPC) versus nab-paclitaxe or TPC in patients for basal-like immune suppressed (BLIS) subtype of triple-negative breast cancer (TNBC) in the first-line teatment of unresectable locally advanced or metastatic TNBC.

Amendment record 6 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 6 times since 2023-03-28; most recent amendment 2026-03-22. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT05806060
Lead Sponsor Fudan University
Conditions Triple-Negative Breast Cancer
Enrollment 134 participants
Start Date 2023-04-25
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-25